Eli Lilly’s Omvoh achieves comprehensive disease control in 27.7% of ulcerative colitis patients at one year
Eli Lilly announced Oct. 15, 2026, that new Omvoh analyses showed corticosteroid-free disease control in ulcerative colitis and Crohn's disease at one year. Omvoh outperformed placebo on combined disease-control measures, including among patients with prior biologic treatment failure. Patients achieving these outcomes